ERBB2 and breast cancer: Moreover, Othman et al., in a phase II/III RCT, placebo-controlled study, involving 140 subjects with invasive non-metastatic BC, demonstrated that positive Her2 or negative estrogen receptor (ER) status seemed to predict pCR in the metformin-treated arm.